BioTech Foods
Our Team

Carlos Villalain - CEO and Co-Founder - Biotech Foods Team

Carlos Villalain
CEO and co-founder

Holds an Economics and Business B.S. from Basque Country University (Spain). He has wide experience in business management and entrepreneurship. His forward-looking approach allowed him to succeed in companies entering unexplored grounds. He contributed to create the sharing-economy in the lodging industry.

Mercedes Vila - Board member - Biotech Foods Team

Mercedes Vila Juárez
Board Member and co-founder

Received her PhD in Materials Physics from the Autonomous University of Madrid-CSIC, Spain, in 2003. After 5 years of international post-doctoral experience on the modification of biomaterials surfaces, she spent 5 more years as Ramon y Cajal Researcher in one of the most prominent research groups in Regenerative Medicine, at the Universidad Complutense de Madrid, Spain. Her research in the last 11 years has been focused on cell-materials surface interactions. She has been awarded with the LÓreal-UNESCO Award “For Women in Science” (2010) and with three Marie Curie actions (IntraEuropean, Reintegration and Society & Enterprise). In 2013 she joined University of Aveiro (Portugal) as Principal Investigator and in 2015 she made the transition to Industry as CEO and Scientific Director of the company CTECHnano.

Pablo Munilla - Board member - Biotech Foods Team

Pablo Munilla
Board Member and co-founder

He is CEO of Inter Alloys since 1994. A leading company in importing/exporting raw materials for the steel industry. This company creates a revenue of more than 100 M€ operating in Europe, America, And Africa providing and complete service of provisions, logistics and financing. Also, Pablo is the president of the Board of Inter Alloys & Investments SL focused on investments activities on start-ups. He is also founder of the Why Not foundation in 2010, dedicated to giving support to mental diseases affected patients.

Prof. Pitarke - Board member - Biotech Foods Team

José M. Pitarke
Board Member

Prof. Pitarke studied Physics at the University of the Basque Country, where he received his PhD degree (with distinction) in 1990 studying some aspects of tunneling spectroscopy and electron and photon emission in solids. After a postdoctoral stay at the Oak Ridge National Laboratory (USA) in the group of Rufus Ritchie, he obtained, in 1993, a permanent position at the University of the Basque Country, where he has been full professor of Condensed Matter Physics since 2000. Prof. Pitarke is By-Fellow of the Churchill College of the University of Cambridge since 2005. He is also the Director of the Nanoscience Cooperative Research Center nanoGUNE since its creation in 2006.

Moni_BTF_BN_blue

Mónica Cicuéndez
Development Director

Obtained her PhD in Bioinorganic Chemistry from the Universidad Complutense de Madrid in 2014. After her project at the Department of Immunology, Hospital Universitario “Ramón y Cajal”, she joined in 2006 the company Marine Biotechnology Biopharmaceutical “PharmaMar” in its European Headquarters. During her PhD, she focused on the development of nanocomposites and bioceramic for bone tissue regeneration. During this period, (2012) she performed an international stay in the Dept. Pharmacy, Biomedical Center. Uppsala University (Sweden) studying the role of materials surface chemistry in the cellular response. She is an expert on cell isolation and in vitro studies of the interactions of different cell types involved in the formation of tissue.

Teresa_BTF_BN_blue02

Teresa Lull Bueno
Process engineer

Bachelor in Pharmacy at the University of Valencia and MSc in Industrial Biotechnology at the IUCT Institute in Barcelona in 2015.
Before joining Biotech Foods, has developed her professional career as an Upstream Scientist within the R&D department of the company 3P Biopharmaceuticals during the last three years.
She is an expert in the development of bioprocess with bioreactors at small and medium scale, both prokaryotic and mammalian cells, optimizing fermentation parameters and culture media as well as improving recombinant proteins and monoclonal antibodies (mAbs) production yield.